Pfizer Inc PFE

Alternate Symbol(s): N.PFE

Healthcare

Pfizer Inc. is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. Its Biopharma segment is engaged in the science-based biopharmaceutical business. Its Biopharma segment includes the Pfizer Oncology Division, the Pfizer U.S. Commercial Division, and the Pfizer International Commercial Division. Its product categories include oncology, primary care and specialty care. Its Oncology products include Ibrance, Xtandi, Inlyta, Bosulif, Lorbrena, Braftovi, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio and Tivdak. Its primary care products include Eliquis, Nurtec ODT/Vydura, Comirnaty, the Prevnar family, Abrysvo, FSME/IMMUN-TicoVac, Paxlovid and Lucira by Pfizer. Its specialty care products include Xeljanz, Enbrel (outside the U.S. and Canada), Inflectra, Cibinqo, Litfulo, Vyndaqel family, Genotropin, Sulperazon, Zavicefta, Medrol and Panzyga.

NYSE:PFE - Post by User

Pfizer Inc

<< Previous

Bullboard Posts

Next >>

Post by KandiBirdBoyon May 10, 2021 10:12am

205 Views

Post# 33164316

✨ GOLD PROXY ONLY $HUGE FSD PHARMA SHAREHOLDERS VS CEO 🏆

Change is Needed Now

Dr. Raza Bokhari, FSD’s Chief Executive Officer, and his hand picked board members have:

failed to address the dramatic loss of shareholder value, with the Company’s shares trading over 97% lower than when Dr. Bokhari was appointed Interim Chief Executive Officer;
massively diluted shareholder interests by issuing almost 16 million shares at low prices, increasing the number outstanding by over 83% in just seven weeks;
awarded over $5.7 million of bonus share compensation to Dr. Bokhari in February 2021 for services yet to be provided and close to $1 million in shares and/or cash to the other directors (Stephen Buyer, Robert Ciaruffoli, James Datin, Gerald Goldberg and Larry Kaiser), the latter amount being almost twice the previous year’s compensation;
caused FSD to reimburse Dr. Bokhari’s privately owned and controlled company for over $1.4 million of expenses in 2020, with limited transparency or explanation;
failed to effectively implement the Company’s business plan to become a pharmaceutical and biotechnology company, having to date failed to meet any of their modest stated goals; and
denied shareholders any say on the change of the Company’s strategic focus, failing to hold a shareholders’ meeting in 2020 and seeking to delay holding a meeting in 2021.

Back to Success

If elected at the upcoming shareholder meeting on May 14, 2021, our nominees hope to restore FSD by:

acquiring biotechnology assets focused on legal medical cannabis and/or legal psychedelics to increase the Company’s drug development pipeline and reduce reliance on a single compound;
auditing the Company’s current Phase 2 clinical trial to determine its current viability and better understand the risks and costs so that appropriate budgets can be created and followed and to determine whether it should be continued;

implementing a strong financial and corporate governance framework so that directors and management are restricted in granting compensation to themselves at levels higher than industry standards;
implementing audits of prior compensation and expenses incurred by the Company; and
developing a robust investor relations function to better communicate FSD’s value to the investment community